All tests benefits:
Fast Turnaround: Quantitative results within 10–15 minutes at the point of care.
High Sensitivity: Accurately detects tear IgE levels, even at low concentrations, allowing for early identification of allergic responses.
Small Sample Volume: Requires only 1–2 µL of tear fluid, ensuring patient comfort and efficient workflow.
Barcode-Linked Protocol: Each cassette includes a unique barcode, allowing the analyzer to automatically select the correct test settings—no manual calibration or software updates required.
Integrated Safety and Quality Control: Built-in validation and system checks ensure test reliability and reproducibility across every clinical setting.
Matrix Metalloproteinase-9 (MMP-9) is an enzyme linked to the breakdown of corneal epithelial barrier function and inflammation in DED. MMP-9 is a critical biomarker associated with ocular surface inflammation in Dry Eye Disease (DED). Elevated levels are associated with more severe disease and poorer ocular surface health.
Used with the i-ImmunDx™ Analyzer, the MMP-9-POC test is a quantitative point-of-care assay designed to detect Matrix Metalloproteinase-9 (MMP-9) in tear fluid. The test provides clinicians with a rapid and objective tool to assess inflammatory status, improving diagnostic precision and treatment guidance.
MMP9-POC Clinical Applications:
- DED Subtyping and Management:
– Discriminate Inflammatory DED vs Non-inflammatory DED;
– Treatment Selection: prescribe anti-inflammatory treatment or not and for how long;
- Monitoring Severity and Efficacy: Severity Assessment; Efficacy Monitoring and Treatment Optimization;
- Preoperative Management: Evaluation of ocular surface inflammation and health before and after Cataract and refractive surgery to reduce post surgical complications.
For more information, please contact us at sales@seindabio.com.
MMP9-POC Brochure
Quantifying Immune Balance in Dry Eye Disease
The LTA-POC is a rapid, quantitative immunoassay developed to measure Lymphotoxin-α (LTA) levels in human tear samples.
Utilizing Seinda’s proprietary i-ImmunDx™ Analyzer, this test provides clinicians with precise insights into ocular surface immune homeostasis, facilitating accurate diagnosis and patient stratification in dry eye disease (DED).
Clinical Significance:
LTA plays a pivotal role in maintaining ocular immune tolerance by activating regulatory T cells (Tregs) through the TNFR2 pathway. Reduced LTA levels in tears have been associated with disrupted immune homeostasis, a key factor in the pathogenesis of DED. By quantifying LTA, the LTA-POC test aids in identifying patients with immune-mediated DED, supporting personalized treatment strategies and monitoring therapeutic efficacy.
Key Features:
- Rapid Results: Delivers quantitative measurements within 10–15 minutes at the point of care.
- High Sensitivity and Specificity: Detects LTA concentrations as low as 1 picogram, ensuring reliable assessment of immune status.
- Minimal Sample Requirement: Requires only 1–2 µL of tear fluid, enhancing patient comfort and ease of collection.
- Integrated Quality Control: Each test cassette contains a unique barcode, enabling the i-ImmunDx™ Analyzer to automatically apply the correct calibration and protocol, ensuring test integrity and eliminating the need for manual updates when new tests are introduced.
Why Choose LTA-POC:
Traditional diagnostic methods for DED often lack specificity and fail to correlate with disease severity. The LTA-POC test addresses this gap by providing objective, molecular-level data on immune status, enabling clinicians to differentiate between DED subtypes and tailor interventions accordingly.
For more information, please contact us at sales@seindabio.com.
LTA-POC Brochure
Rapid Detection of Allergic Conjunctivitis
The IgE-POC is a point-of-care diagnostic test developed to measure total Immunoglobulin E (IgE) levels in tear fluid—offering a rapid, objective solution for the detection and assessment of allergic conjunctivitis.Designed for use with the i-ImmunDx™ Analyzer, this test enables clinicians to confirm allergy-related inflammation in minutes, improving diagnostic accuracy and supporting more targeted treatment decisions.
Clinical Value:
Allergic conjunctivitis can be difficult to distinguish from other forms of ocular surface inflammation based on symptoms alone. The IgE-POC test provides molecular-level confirmation, helping clinicians differentiate allergic from non-allergic causes of eye irritation and enabling more precise treatment planning—including appropriate use of antihistamines or anti-inflammatory therapies.
Key Features:
- Fast Turnaround:
Quantitative results available within 10–15 minutes at the point of care. - High Sensitivity:
Accurately detects tear IgE levels, even at low concentrations, allowing for early identification of allergic responses. - Small Sample Volume:
Requires only 1–2 µL of tear fluid, ensuring patient comfort and efficient workflow. - Integrated Quality Control:
Each test cassette contains a unique barcode, enabling the i-ImmunDx™ Analyzer to automatically apply the correct calibration and protocol, ensuring test integrity and eliminating the need for manual updates when new tests are introduced.
Why Choose IgE-POC:
- Objective confirmation of allergy-related eye disease
- Supports differential diagnosis in multifactorial dry eye or ocular discomfort
- Simple, quick, and deployable in routine clinical practice
For more information, please contact us at sales@seindabio.com
IgE-POC Brochure
Launching in 2026
Launching in 2026